NCT05090033 - Characterizing the Use of Ofatumumab in a Real World Setting | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Relapsing Multiple Sclerosis

Interventions

OTHER

ofatumumab

There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (7)

2065

Novartis Investigative Site, St Leonards

2139

Novartis Investigative Site, Concord

3004

Novartis Investigative Site, Melbourne

3084

Novartis Investigative Site, Heidelberg

3168

Novartis Investigative Site, Clayton

4222

Novartis Investigative Site, Southport

6009

Novartis Investigative Site, Nedlands